Kisten ras mutations in patients with colorectal cancer: the “RASCAL II” study.

This collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it predispose to more aggressive biological behaviour in patients with advanced colorectal cancer